These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 31283097)

  • 1. What will it take to refute the possible safety signal for dolutegravir and neural tube defects?
    Zash RM
    BJOG; 2019 Oct; 126(11):1346. PubMed ID: 31283097
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons from dolutegravir and neural tube defects.
    Abrams E; Myer L
    Lancet HIV; 2021 Jan; 8(1):e3-e4. PubMed ID: 33387476
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
    Mofenson LM; Pozniak AL; Wambui J; Raizes E; Ciaranello A; Clayden P; Ehrenkranz P; Fakoya A; Hill A; Khoo S; Mahaka I; Modi S; Moore C; Phillips A; Siberry G; Sikwese K; Thorne C; Watts HD; Doherty M; Ford NP
    J Int AIDS Soc; 2019 Jul; 22(7):e25352. PubMed ID: 31298496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two cases of neural tube defects with dolutegravir use at conception in south Brazil.
    Kreitchmann R; Oliveira FR; Sprinz E
    Braz J Infect Dis; 2021; 25(2):101572. PubMed ID: 33852885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.
    Zash R; Makhema J; Shapiro RL
    N Engl J Med; 2018 Sep; 379(10):979-981. PubMed ID: 30037297
    [No Abstract]   [Full Text] [Related]  

  • 6. Dolutegravir-induced neural tube defects in mice are folate responsive: Erratum.
    AIDS; 2024 Aug; 38(10):1607. PubMed ID: 38990319
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing the risk of dolutegravir for women of childbearing potential.
    Schomaker M; Davies MA; Cornell M; Ford N
    Lancet Glob Health; 2018 Sep; 6(9):e958-e959. PubMed ID: 30049617
    [No Abstract]   [Full Text] [Related]  

  • 8. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
    Chouchana L; Beeker N; Treluyer JM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
    Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
    Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
    Money D; Lee T; O'Brien C; Brophy J; Bitnun A; Kakkar F; Boucoiran I; Alimenti A; Vaudry W; Singer J; Sauve LJ;
    BJOG; 2019 Oct; 126(11):1338-1345. PubMed ID: 31188522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No developmental toxicity observed with dolutegravir in rat whole embryo culture.
    Posobiec LM; Chapman SP; Murzyn SF; Rendemonti JE; Stanislaus DJ; Romach EH
    Birth Defects Res; 2021 Oct; 113(16):1190-1197. PubMed ID: 34453500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to the editor in re: Mohan et al., 2020 'dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels'.
    Romach EH; Posobiec LM; Bloomer JC; Zamek-Gliszczynski MJ; Stanislaus DJ
    EBioMedicine; 2021 Apr; 66():103335. PubMed ID: 33857900
    [No Abstract]   [Full Text] [Related]  

  • 14. The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
    Laker EAO; Arinaitwe A; Owarwo N; Onzia A; Nasasira B; Wailagala A; Kalule I; Anguzu G; Kiragga A; Seden K; Lwanga I; Castelnuovo B; Musomba R; Lamorde M
    Drug Saf; 2020 Nov; 43(11):1133-1140. PubMed ID: 32926356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
    Nguyen B; Foisy MM; Hughes CA
    Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and placental transfer of dolutegravir in pregnancy.
    Ikumi NM; Anumba D; Matjila M
    J Antimicrob Chemother; 2022 Feb; 77(2):283-289. PubMed ID: 34618029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In response to the Letter to the Editor by Romach et al. re our publication "Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels".
    Mohan H; Guzman Lenis M; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
    EBioMedicine; 2021 Apr; 66():103334. PubMed ID: 33862586
    [No Abstract]   [Full Text] [Related]  

  • 18. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
    Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifying dolutegravir to PrEPare for long life.
    Mandarino A
    Commun Biol; 2022 Nov; 5(1):1193. PubMed ID: 36344610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.